After pausing a trial for a Moderna-partnered cystic fibrosis candidate due to subpar tolerability, Vertex Pharmaceuticals has now decided to discontinue the program entirely. Vertex initially paused ...

It has been over four months since I last covered Vertex Pharmaceuticals (VRTX), where I discussed how the company was still the unquestionable leader in cystic fibrosis (CF) but was working to ...

A Vertex Pharmaceuticals immunology drug in clinical testing for a rare kidney disease is catching up to others that work in a similar way, but the company contends its therapy can be best in its ...

Vertex Pharmaceuticals said its drug for a rare kidney condition succeeded in a Phase 3 trial. The drug, povetacicept, is a central piece of the company's plan to expand into kidney disease. Vertex ...

Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77. Vertex said Monday that a drug it secured ...

March 9 (Reuters) - Vertex Pharmaceuticals (VRTX.O), opens new tab said on Monday that its experimental drug sharply reduced a key sign of kidney damage in a late‑stage ‌trial, putting the company on ...

I’ve had my Shark Rocket HV301 for seven years, and it has never let me down on hardwood floors, high-pile area rugs, or tile. Recently, I moved into a larger apartment with more furniture, more ...

Cystic fibrosis (CF) specialist Vertex is tracking two newer launches that speak to its efforts to expand its prowess beyond those roots. Despite mixed early results for those rollouts so far, the ...

Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77. Vertex executives warned that Casgevy, its ...

Follow this author to personalize your feed and get instant alerts. WHY FOLLOW? Custom Feed: See the stories that matter most to you. Smart Alerts: Get notified about major news as it happens. Update ...